Subscribe

SYN-TECH Chem. & Pharm. Co., Ltd. (1777.TWO)

TWD75.30 +0.50 (+0.67%)
TW TWO Healthcare Medical - Pharmaceuticals
Address No. 168 Kai Yuan Road 73055
Tainan, TW
CEO Chun Cheng Hung
Website syn-tech.com.tw
IPO 2007-12-31
ISIN TW0001777001

Explore sections of this company profile

Description

SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relaxant, antitussive, antipruritic, scabicide, anti-inflammatory, antipyretic, analgesic, muscle relaxant, anxiolytic, antiemetic, anticonvulsant, anti-ulcerative, antihypertensive, a-blocker, vasodilator, bronchodilator, anxiolytic, tranquilizer, local anesthetic, decongestant, antispasmodic, neuroprotective, antimigraine, pharmaceutic aid/lubricant, antiglaucoma agent, hyponatremia, antidepressant, sedative, and analgesic, as well as treatment for hyperparathyroidism and urinary frequency, benign prostatic hypertrophy, and Herpes virus helicase-primase inhibitor. SYN-TECH Chem. & Pharm. Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD75.30 +0.50 (+0.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
30.3K
Beta
-0.06
Float Shares
31.84M
Free Float %
71.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.71% -2.36% -2.64% -2.09% -8.24% -4.88% -20.95% -19.86% -13.83% -22.40% +274.60%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
75.30
DCF (Unlevered) 217.20 +188.4%
DCF (Levered) 389.77 +417.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.06
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +3.4% Q1'26: -12.7% (vs Q1'25)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -33.6% Q1'26: -5.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +39.9% Q1'26: +10.2% (vs Q1'25)
  • ✓
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +24.6% ★ Q1'26: +28.2% (vs Q1'25)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +14.2% ★ Q1'26: +15.2% (vs Q1'25)
  • ✗
    Share dilution Medical - Pharmaceuticals: +0.0%
    +0.0% Q1'26: +0.3% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    0.49× ★ Q1'26: 0.51× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.08) × ERP
WACC = 93% × Ke + 7% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 213.69 Current price: 75.30
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2017
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
694.00M
est.
694.99M
est: 694.00M (+0.1%)
946.41M
est: 930.00M (+1.8%)
983.79M
est: 1.00B (-1.6%)
893.23M
est: 744.00M (+20.1%)
986.30M
est: 951.00M (+3.7%)
1.11B
est: 1.10B (+1.6%)
930.00M
930.00M – 930.00M
-15.2% YoY
1.00B
1.00B – 1.00B
+7.5% YoY
744.00M
744.00M – 744.00M
-25.6% YoY
951.00M
951.00M – 951.00M
+27.8% YoY
1.10B
1.10B – 1.10B
+15.4% YoY
EBITDA
252.83M
est.
152.72M
est: 252.83M (-39.6%)
270.18M
est: 338.81M (-20.3%)
333.14M
est: 364.31M (-8.6%)
240.04M
est: 271.04M (-11.4%)
319.08M
est: 346.46M (-7.9%)
430.56M
est: 399.65M (+7.7%)
482.97M
482.97M – 482.97M
+20.9% YoY
519.32M
519.32M – 519.32M
+7.5% YoY
386.38M
386.38M – 386.38M
-25.6% YoY
493.88M
493.88M – 493.88M
+27.8% YoY
569.70M
569.70M – 569.70M
+15.4% YoY
EBIT
190.56M
est.
101.48M
est: 190.56M (-46.7%)
200.61M
est: 255.36M (-21.4%)
262.37M
est: 274.58M (-4.4%)
168.59M
est: 204.29M (-17.5%)
238.23M
est: 261.12M (-8.8%)
319.51M
est: 301.21M (+6.1%)
345.49M
345.49M – 345.49M
+14.7% YoY
371.50M
371.50M – 371.50M
+7.5% YoY
276.39M
276.39M – 276.39M
-25.6% YoY
353.29M
353.29M – 353.29M
+27.8% YoY
407.53M
407.53M – 407.53M
+15.4% YoY
Net Income
209.51M
est.
59.78M
est: 209.51M (-71.5%)
159.47M
est: 245.36M (-35.0%)
186.74M
est: 270.84M (-31.1%)
177.16M
est: 127.39M (+39.1%)
295.29M
est: 310.64M (-4.9%)
251.01M
est: 259.24M (-3.2%)
245.41M
245.41M – 245.41M
-5.3% YoY
270.91M
270.91M – 270.91M
+10.4% YoY
127.41M
127.41M – 127.41M
-53.0% YoY
310.71M
310.71M – 310.71M
+143.9% YoY
259.30M
259.30M – 259.30M
-16.5% YoY
SGA
59.10M
est.
65.35M
est: 59.10M (+10.6%)
74.09M
est: 79.20M (-6.5%)
81.92M
est: 85.17M (-3.8%)
86.29M
est: 63.36M (+36.2%)
89.91M
est: 80.99M (+11.0%)
89.73M
est: 93.43M (-4.0%)
75.93M
75.93M – 75.93M
-18.7% YoY
81.64M
81.64M – 81.64M
+7.5% YoY
60.74M
60.74M – 60.74M
-25.6% YoY
77.64M
77.64M – 77.64M
+27.8% YoY
89.56M
89.56M – 89.56M
+15.4% YoY
EPS
4.69
est.
1.92
est: 4.69 (-59.0%)
5.13
est: 5.49 (-6.5%)
6.00
est: 6.06 (-1.0%)
5.03
est: 2.85 (+76.5%)
6.62
est: 6.95 (-4.7%)
5.63
est: 5.80 (-2.9%)
5.49
5.49 – 5.49
-5.4% YoY
6.06
6.06 – 6.06
+10.4% YoY
2.85
2.85 – 2.85
-53.0% YoY
6.95
6.95 – 6.95
+143.9% YoY
5.80
5.80 – 5.80
-16.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-11 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-08 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-07 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-06 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-05 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-05-04 A 4/5 4/5 4/5 5/5 3/5 3/5 4/5
2026-04-30 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-29 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-28 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-27 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-24 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-23 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-22 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
376.09M
OE per share TTM
8.42
Owner's Yield
11.83%
Maintenance CapEx ratio
1.54%
Maint CapEx / Avg PPE
103.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 66.3K 0.39%
2 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 11.8K 0.29%
3 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 9.4K 0.28%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.36M
Shares Outstanding
44.59M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Mei Qi Zhuang Accounting Supervisor — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals